In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1 and superior in reducing sweat chloride compared to ...

The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...

A new once daily triple drug treatment for cystic fibrosis is set to be “immediately funded” by NHS England following recommendation from the National Institute for Health and Care Excellence (NICE).1 ...

NHS patients in England with cystic fibrosis will be among the first in Europe to access a new treatment for their condition, ...

Vertex Pharmaceuticals’ stock dipped 1.73%, underperforming the S&P 500’s mild loss, despite solid monthly gains. Investors ...